Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanju Chen

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Small (Weinheim an Der Bergstrasse, Germany)|June 6, 2022
Atomically Dispersed CoN<sub>3</sub> C<sub>1</sub> -TeN<sub>1</sub> C<sub>3</sub> Diatomic Sites Anchored in N-Doped Carbon as Efficient Bifunctional Catalyst for Synergistic Electrocatalytic Hydrogen Evolution and Oxygen ReductionMinmin Wang, Xiuhui Zheng, Donglin Qin, et al.
Environmental Science & Technology|July 27, 2019
A Multiplatform Inversion Estimation of Statewide and Regional Methane Emissions in California during 2014-2016Yu Yan Cui, Abhilash Vijayan, Matthias Falk, et al.
Nature Medicine|January 14, 2022
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Small (Weinheim an Der Bergstrasse, Germany)|June 6, 2022
Atomically Dispersed CoN<sub>3</sub> C<sub>1</sub> -TeN<sub>1</sub> C<sub>3</sub> Diatomic Sites Anchored in N-Doped Carbon as Efficient Bifunctional Catalyst for Synergistic Electrocatalytic Hydrogen Evolution and Oxygen ReductionMinmin Wang, Xiuhui Zheng, Donglin Qin, et al.
Environmental Science & Technology|July 27, 2019
A Multiplatform Inversion Estimation of Statewide and Regional Methane Emissions in California during 2014-2016Yu Yan Cui, Abhilash Vijayan, Matthias Falk, et al.
Nature Medicine|January 14, 2022
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 4